Eugene Braunwald.

David A. Morrow, M .D., M.P.H., Eugene Braunwald, M.D., Marc P. Bonaca, M.D., Sebastian F. Ameriso, M.D., Anthony J. Dalby, M.B., Ch.B., Mary Polly Seafood, B.A., Keith A.A. Fox, M.B., Ch.B., Leslie J. Lipka, M.D., Ph.D., Xuan Liu, Ph.D.D., Ph.D., A.J. Oude Ophuis, M.D., Ph.D., Ernesto Paolasso, M.D., Benjamin M. Scirica, M.D., M.P.H., Jindrich Spinar, M.D., Ph.D., Pierre Theroux, C.M., M.D., Stephen D. Wiviott, M.D., John Strony, M.D., and Sabina A. Murphy, M.P.H. In individuals with severe coronary syndromes, the use of powerful platelet inhibitors has been shown to reduce the rate of thrombotic events at the expense of increased bleeding.1-3 In contrast, among patients with stable atherosclerosis, a reduced rate of thrombotic events with antiplatelet therapy furthermore to aspirin therapy is not established.4 Thrombin is a serine protease that’s critical in thrombosis.

Arterial events occurred in eight sufferers in the aspirin group and in five individuals in the placebo group . Additional Observations Five patients had a detrimental event that was considered to be due to the research treatment and resulted in discontinuation of the medication. These events were gastric pain in three patients , a cutaneous reaction in one aspirin-treated affected individual, and renal failure in another aspirin-treated patient. A sign for antiplatelet therapy apart from an severe arterial event occurred in five patients in the aspirin group and in three individuals in the placebo group, and an indication for anticoagulant therapy other than recurrent venous thromboembolism occurred in 3 sufferers and in two patients in the two groups, respectively.